Cited by 57Acute Myeloid Leukemia ResearchHematopoietic Stem Cell TransplantationBlood disorders and treatments

Chronic interleukin-1 exposure triggers selection for Cebpa -knockout multipotent hematopoietic progenitors

Open access
Higa, Kelly C., Goodspeed, Andrew, Chavez, James S., De Dominici, Marco, Danis, Etienne, Zaberezhnyy, Vadym, Rabe, Jennifer L., Tenen, Daniel G. +2 more·2021·Journal of Experimental Medicine

Published version of a preprint

Abstract

The early events that drive myeloid oncogenesis are not well understood. Most studies focus on the cell-intrinsic genetic changes and how they impact cell fate decisions. We consider how chronic exposure to the proinflammatory cytokine, interleukin-1β (IL-1β), impacts Cebpa-knockout hematopoietic stem and progenitor cells (HSPCs) in competitive settings. Surprisingly, we found that Cebpa loss did not confer a hematopoietic cell–intrinsic competitive advantage; rather chronic IL-1β exposure engendered potent selection for Cebpa loss. Chronic IL-1β augments myeloid lineage output by activating differentiation and repressing stem cell gene expression programs in a Cebpa-dependent manner. As a result, Cebpa-knockout HSPCs are resistant to the prodifferentiative effects of chronic IL-1β, and competitively expand. We further show that ectopic CEBPA expression reduces the fitness of established human acute myeloid leukemias, coinciding with increased differentiation. These findings have important implications for the earliest events that drive hematologic disorders, suggesting that chronic inflammation could be an important driver of leukemogenesis and a potential target for intervention.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1084/jem.20200560

Cites

90 of 91 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Cebpa-deficient MPPGM show nearly identical patterns of overexpression in genes like Bmi1, Foxo3 and Mycn.

    “Our previously published analysis (Higa et al., 2021) of Cebpa-deficient MPPGM shows nearly identical patterns of overexpression in genes like Bmi1, Foxo3 and Mycn (Tothova et al., 2007; Takubo et al., 2010; Merchant et al., 2011; Warr et al., 2013; Murakami et al., 2014; Scognamiglio et al., 2016).”

    From PU.1 is required to restrain myelopoiesis during chronic inflammatory stress (2023) · cites this paper as Higa et al., 2021

    The Results section (‘IL-1β triggers aberrant expansion potential of Cebpa-knockout MPP3s’; page unavailable) reports elevated Bmi1, Foxo3 and Mycn expression in Cebpa-deficient, GM-biased MPP3s cultured with IL-1β. The claim omits that treatment condition, and the cited paper does not establish the asserted ‘nearly identical’ pattern of overexpression. (LLM, conf=0.80)

    Experimental — accuracy not yet measured
  • Cebpa-deficient MPPGM show identical patterns of gene expression to PU.1 KI/KI MPPGM.

    “It is noteworthy that we observed identical patterns of gene expression (Higa et al., 2021) in Cebpa-deficient MPPGM.”

    From PU.1 is required to restrain myelopoiesis during chronic inflammatory stress (2023) · cites this paper as Higa et al., 2021

    The Results section, “Chronic IL-1β–driven myeloid gene programs are Cebpa dependent” (page unavailable), reports gene-expression changes in Cebpa-deficient, GM-biased MPP3s. It does not compare those cells with PU.1 KI/KI MPPGM or establish that their expression patterns are identical. (LLM, conf=0.84)

    Experimental — accuracy not yet measured
  • Cebpa-deficient MPPGM retained high expression levels of stem cell genes including Foxo3, Mycn, Bmi1 and Bcl2 following chronic exposure to IL-1β.

    “These data are strongly reminiscent of Cebpa-deficient MPPGM, which likewise retained high expression levels of stem cell genes including Foxo3, Mycn, Bmi1 and Bcl2 following chronic exposure to IL-1β (Higa et al., 2021).”

    From PU.1 is required to restrain myelopoiesis during chronic inflammatory stress (2023) · cites this paper as Higa et al., 2021

    The Results section, “Chronic IL-1β triggers a self-renewal gene program in Cebpa-knockout MPP3s” (page unavailable), reports elevated Bmi1, Foxo3, and Mycn in Cebpa-deficient MPP3s after chronic IL-1β exposure. It names Mpl as the fourth gene, not Bcl2; our copy does not support the claim about Bcl2. (LLM, conf=0.88)

    Experimental — accuracy not yet measured
  • IL-1 can trigger the selective expansion of Cebpa-deficient HSPCs in a mouse model of oncogenic BM competition.

    “we found that IL-1 can trigger the selective expansion of Cebpa-deficient HSPCs in a mouse model of oncogenic BM competition (Higa et al., 2021).”
  • IL-1β-mediated repression of these genes may involve other transcriptional regulators aside from PU.1 including CEBPA.

    “These data suggest IL-1β-mediated repression of these genes may involve other transcriptional regulators aside from PU.1 including CEBPA, which regulates many of the same genes (Koschmieder et al., 2005; Pundhir et al., 2018; Higa et al., 2021).”

    From PU.1 is required to restrain myelopoiesis during chronic inflammatory stress (2023) · cites this paper as Higa et al., 2021

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Higa, K. C., Goodspeed, A., Chavez, J. S., De Dominici, M., Danis, E., Zaberezhnyy, V., Rabe, J. L., Tenen, D. G., Pietras, E. M., & DeGregori, J.
Affiliations
  • University of Colorado Anschutz (US)
  • University of Colorado Cancer Center (US)
  • Department of Biochemistry and Molecular Genetics, University of Colorado Anschutz Medical Campus, Aurora, CO 1
  • Harvard University (US)
Corresponding author
DeGregori, James
Venue
Journal of Experimental Medicine
Published
2021-04-29
Volume
218
Issue
6
ISSN
  • 0022-1007 (ISSN-L)
  • 1540-9538
OpenAlex
W3157426827
Cited by
57
References
91
Citations by year
2026: 5 · 2025: 10 · 2024: 10 · 2023: 13 · 2022: 12 · 2021: 6 · 2020: 1
FWCI
6.70
Type
journal article
Language
en
Open access
Locations
  • The Journal of Experimental Medicine (publishedVersion, cc-by-nc-sa)
  • bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by-nd)
  • PubMed Central (publishedVersion, cc-by-nc-sa)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health (R01-AG066544, R01-AG067584, R01-DK119394, R35-CA197697, P01-HL131477, F30-CA210383, T32-AG000279, F31-HL138754)
  • Cleo Meador and George R. Scott Endowed Chair of Medicine in Hematology
  • Department of Medicine Outstanding Early Career Scholar Program
  • Leukemia and Lymphoma Society (7020-19)
  • Courtenay C. and Lucy Patten Davis Endowed Chair in Lung Cancer Research
  • National Cancer Institute (P30-CA046934)
Topics
  • Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
  • Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Blood disorders and treatments
Keywords
IL-1β, CEBPA, hematopoietic stem and progenitor cells, leukemogenesis, chronic inflammation, competitive fitness, myeloid differentiation, acute myeloid leukemia
MeSH terms
Animals, Cell Differentiation, Cell Line, Hematopoietic Stem Cells, Humans, Inflammation, Mice, Inbred C57BL, Leukemia, Myelomonocytic, Acute, Gene Expression, Hematopoietic Stem Cell Transplantation, Cell Lineage, Myeloid Cells, CCAAT-Enhancer-Binding Proteins, Mice, Interleukin-1beta, HEK293 Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review